Clinical Trials Browser

Phase 2 × Interventional × Everolimus × Clear all

NCT04665739 2026-04-16

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06955169 2026-04-16

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT05773274 2026-04-15

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT07340541 2026-04-13

EVOLVE-BDT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Phase 2 Not yet recruiting

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 2 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02397083 2026-02-13

LEVER

Phase 2 Active not recruiting

Endometrial Hyperplasia

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

Neoplasm Metastasis

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT06326190 2025-09-16

LUMEN-1

Phase 2 Recruiting

Meningioma

NCT02029001 2025-08-07

MOST plus

Phase 2 Recruiting

Neoplasm Metastasis

NCT01141309 2025-07-22

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Diseases, Thyroid Neoplasms

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Phase 2 Active not recruiting

53 enrolled 12 charts

Breast Neoplasms

NCT00087685 2025-05-01

RAD001 in Recurrent Endometrial Cancer Patients

Phase 2 Completed

35 enrolled 6 charts

Uterine Neoplasms, Endometrial Neoplasms

NCT00113360 2025-05-01

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2 Completed

67 enrolled 6 charts

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed

10 enrolled 4 charts

Mastocytosis, Systemic

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms

NCT03114527 2025-04-04

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2 Active not recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT06126588 2025-03-11

ELUMEN

Phase 2 Recruiting

Meningioma

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Phase 2 Completed

103 enrolled 16 charts

Breast Neoplasms

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT02216786 2024-12-02

MANTA

Phase 2 Completed

Estrogen Receptor Positive Breast Cancer

NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

21 enrolled 8 charts

Neuroendocrine Tumors

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01678664 2024-09-25

EVACEL

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00811590 2024-09-19

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Phase 2 Terminated

3 enrolled 4 charts

Neoplasms, Peutz-Jeghers Syndrome, Polyps

NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Phase 2 Completed

74 enrolled 13 charts

Advanced, Persistent, or Recurrent Endometrial Cancer

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06561022 2024-08-19

abemaSNF1/3

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04803318 2024-06-25

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT02155920 2024-05-08

Everolimus for Children With Recurrent or Progressive Ependymoma

Phase 2 Completed

11 enrolled 13 charts

Familial ependymoma, Ependymoma

NCT06301386 2024-03-08

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms

NCT01345136 2024-02-13

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Phase 2 Terminated

Neuroma, Acoustic, Neurofibromatosis 2

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms